CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

FJ Manzano Lista; AR Rubio Salvador; N Labrador Andújar; JM Martínez Sesmero; M García Palomo; J Mateos Rubio; JJ Cia Lecumberri; P Moya Gómez

doi:10.1136/ejhpharm-2016-000875.207

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Clinical pharmacy

CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Lista FM, Salvador AR, Andújar NL, et al

CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

European Journal of Hospital Pharmacy 2016;23:A91-A92.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password